Corvas, Vascular Genomics Inc. deal

CVAS received a three-year option to acquire Vascular Genomics, a privately held company that develops vascular targeting technology. CVAS would make the purchase with

Read the full 245 word article

How to gain access

Continue reading with a
two-week free trial.